Understanding compound selectivity and pocket druggability with data-driven drug design

Understanding compound selectivity and pocket druggability with data-driven drug design

This article is brought to you by: 

Selectivity is a crucial property in the development of new active pharmaceutical ingredients (APIs). Binding site comparisons within a protein family are key to understanding how to modulate the selectivity profile of a potential new API, which includes understanding both on- and off-target effects. 

Premium Access
To access this content please enter your details in the fields below. If you believe you have already done so for this, please resubmit your details in the next form down.
Already registered?
If you believe you have already registered please submit the email you originally entered.